劉新華，二級(jí)教授

研究方向：新藥分子設(shè)計(jì)、合成及生物活性研究

電子郵箱：xhliuhx@163.com

辦公室：知行樓B1109

個(gè)人簡(jiǎn)介：

藥物化學(xué)博導(dǎo)，享受省政府津貼。先后畢業(yè)于合肥工業(yè)大學(xué)、貴州大學(xué)(碩士)、南京大學(xué)(博士)，新加坡南洋理工大學(xué)訪問(wèn)教授。皖江學(xué)者、安徽省學(xué)術(shù)與技術(shù)帶頭人、安徽省杰青。先后主持國(guó)家973專項(xiàng)、主持國(guó)家自然科學(xué)基金5項(xiàng)；主持完成安徽省重大科技專項(xiàng)。安徽省藥物化學(xué)專委會(huì)首屆主任委員，安徽省首屆高水平導(dǎo)師。主持完成10多個(gè)新藥臨床前評(píng)價(jià)、在國(guó)內(nèi)首次成功仿制三類新藥2項(xiàng)、主持制定國(guó)家新藥標(biāo)準(zhǔn)2項(xiàng)。以第1獲獎(jiǎng)人獲安徽省自然科學(xué)二等獎(jiǎng)1項(xiàng)、安徽省科技進(jìn)步三等獎(jiǎng)2項(xiàng)。

學(xué)術(shù)兼職2020/01-至今，Medicinal Chemistry編輯

2020/01-至今，Current Topics in Medicinal Chemistry編委

2018/01-至今，安徽省藥物化學(xué)專委會(huì)主任委員2018/01-至今，安徽省藥學(xué)會(huì)常務(wù)理事

科研項(xiàng)目：

(1)靶向Cat C的新型非肽基非共價(jià)抑制劑：優(yōu)化設(shè)計(jì)合成及抗炎活性作用機(jī)制(22377001), 2024.1~2027.12，國(guó)家自然科學(xué)基金面上項(xiàng)目, 60

(2)靶向Dyskerin-NOP10相互作用的特異性小分子：優(yōu)化設(shè)計(jì)合成及抑制端粒

酶活化(21977001), 2020.1~2023.12，國(guó)家自然科學(xué)基金面上項(xiàng)目, 66

(3)抗腫瘤藥物合成的關(guān)鍵技術(shù)與產(chǎn)業(yè)化研究(18030801118),安徽省重大科技

專項(xiàng), 2018.1~2020.12，360

(4)選擇性識(shí)別端粒蛋白p65的苯并吡喃新先導(dǎo)：優(yōu)化設(shè)計(jì)合成及作用機(jī)制,(21572003), 2016.1~2019.12，國(guó)家自然科學(xué)基金面上項(xiàng)目, 78

(5)基于端粒酶TERT靶標(biāo)新先導(dǎo)的設(shè)計(jì)合成與機(jī)制研究, 2014.1~2016.12,安徽省杰出青年基金，30

(6)新型端粒酶TERT抑制劑：手性吡唑-香豆素-色酮新骨架的優(yōu)化設(shè)計(jì)合成及構(gòu)效關(guān)系(21272008), 2013.1~2016.12，國(guó)家自然科學(xué)基金面上項(xiàng)目, 80

(7)新型以手性2H吡唑-噁唑?yàn)橹行亩嚯s環(huán)的設(shè)計(jì)、殺菌活性及構(gòu)效關(guān)系(20902003)，2010.1~2012.12，國(guó)家自然科學(xué)青年基金，19

發(fā)表論文情況：

(1)Duo Ma, Xianan Liu, §Xingxing Zhang, Yaling Hong, Yumeng Wang, Famin Zhang, Leran Du, Junjie Zhao, Quan Wang, Cui Chang, Wenhu Liu, Yan Lou,Xinhua Liu*, Discovery of the 2, 3-dihydrobenzopyrane-4-one as a Potent FTO Inhibitor Against Obesity-related Metabolic Diseases,Journal of Medicinal Chemistry,2025,doi.org/10.1021/acs.jmedchem.4c03124

(2)Ya-Xi Ye, Jian-Cheng Pan, Hai-Chao Wang, Xing-Tao Zhang*, Hai-Liang Zhu*,Xin-Hua Liu*, Advances in small-molecule fluorescent probes for the study of apoptosis,Chemical Society Reviews,2024,53, 9133-9189.

(3)Yao Yao Yan, Xing Xing Zhang, Yun Xiao, Xiao Bao Shen, Yu Jie Jian, Yu Meng Wang,Zi Hao She, Ming Ming Liu*andXin Hua Liu*,Design, Synthesis of 2-amino-pyridine Derivative As a Potent CDK8 Inhibitorfor Anti-colorectal Cancer Therapy,Journal of Medicinal Chemistry,2022,65,13216-13239.

(4)Xing Xing Zhang,Yun Xiao,Yao Yao Yan, Yu Meng Wang, Han Jiang, Lei Wu, Jing-bo Shi,*andXin Hua Liu*,Discovery of the Novel 1H Pyrrolo[2,3 b]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer,Journal of Medicinal Chemistry,2022,65,12095-12123.

(5)Yaoyao Yan, Chen Xing, Yun Xiao, Xiaobao Shen, Zhaoyan Zhang, Chuanbiao He, Jing Bo Shi, Mingming Liu*,Xinhua Liu*, Discovery and Anti-inflammatory Activity Evaluation of Novel CDK8 Inhibitor through Up-regulation of IL-10 for Treatment of Inflammatory Bowel Diseaseinvivo,Journal of Medicinal Chemistry,2022,65, 7334-7362.

(6) Liu Zeng Chen, Xing Xing Zhang, Ming Ming Liu, Jing Wu, Duo Ma, Liang Zhuo Diao, Qingshan Li,Yan Shuang Huang, Rui Zhang, Ban Feng Ruan* andXin Hua Liu*, Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis,Journal of Medicinal Chemistry,2021,64, 13633-13657.

(7)Xing Chen, Yaoyao Yan, Zhaoyan Zhang, Faming Zhang, Mingming Liu, Leran Du, Haixia Zhang, Xiaobao Shen, Dahai Zhao, Jing Bo Shi,* andXinhua Liu*, Discovery and InVivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor, Journal of Medicinal Chemistry,2021,64, 11857-11885.

(8) Yang Wang, Xing Chen, Yaoyao Yan, Ming ming Liu* andXin Hua Liu*, Discovery and SARs of 5-chloro-N4-phenyl-N2-(pyridin-2-yl) pyrimidine-2,4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent anti-tumor activity,Journal of Medicinal Chemistry,2020, 63, 3327-3347.

(9)Mingming Liu, Yuru Liang, Zhongzhen Zhu, Jin Wang, Xingxing Cheng, Jiayi Cheng, Binpeng Xu, Rong Li,Xinhua Liu* and Yang Wang*, Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-inducible Factor (HIF) 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis,Journal of Medicinal Chemistry,2019,62, 9299-9314.

(10)Jing Bo Shi, Liu Zeng Chen, Bao Shi Wang, Xin Huang, Ming Ming Jiao, Ming Ming Liu, Wen-Jian Tang andXin-Hua Liu*, Novel Pyrazolo[4,3-d]pyrimidine as Potent and Orally Active Inducible Nitric Oxide Synthase (iNOS) Dimerization Inhibitor with Efficacy in Rheumatoid Arthritis Mouse Model,Journal of Medicinal Chemistry,2019,62, 4013-4031.

獲獎(jiǎng)情況：

(1)劉新華等，靶標(biāo)端粒酶hTERT的新型活性分子的設(shè)計(jì)合成與作用機(jī)制，安徽省自然科學(xué)二等獎(jiǎng),Z-2020-2-026-R1. 2020年

(2)劉新華等，基于靶標(biāo)與機(jī)制的新型抗炎活性分子的設(shè)計(jì)合成，安徽省自然科學(xué)三等獎(jiǎng), Z-2023-2-037-R1. 2023年

(3)劉新華等，具有藥用價(jià)值的新型雜環(huán)小分子的設(shè)計(jì)合成與生物活性研究,安徽省自然科學(xué)三等獎(jiǎng), 2014-3-R1,2014年

(4)第十五屆安徽青年科技獎(jiǎng)，2013年

專利情況：

(1)劉新華;石靜波;陳冉;王寶石;湯文建;陳留贈(zèng);汪洋;一種嘧啶并吡唑雜環(huán)化合物、制備方法、用途，專利號(hào)：ZL 2017 1 1446400.5；2020.2.18

(2)劉新華，石靜波，胡陽(yáng)生，陳劉贈(zèng)，劉明明，黃馨，王寶石，韓旭，焦明鳴；丹皮酚衍生物、藥物制劑、制備方法與應(yīng)用；專利號(hào)：ZL 2019 1 1329122.4；2023. 3. 21

(3)劉新華，石靜波；一種5-氯-嘧啶-2,4-二胺類化合物及其制備方法和應(yīng)用；專利號(hào)：ZL 2020 1 0241722.1；2023. 5. 9

(4)劉新華，劉明明，石靜波，閆堯瑤，張興星，王宇蒙，肖云江瀚，佘梓濠，吳磊；一種芳基脲類衍生物及其制備方法與應(yīng)用；專利號(hào)：ZL 2022 1 0891463.6；2023. 6. 27

(5)劉新華，石靜波，朱仁德，吳靜，胡陽(yáng)生，張昭燕；一種丹皮酚衍生物及其制備方法、制劑與應(yīng)用；專利號(hào)：ZL 2021 1 0758936.0；2023. 3. 7

(6)劉新華，石靜波，劉明明，張昭燕，陳星，閆堯瑤，肖云；一種5-取代的嘧啶二胺類衍生物及其制備方法與應(yīng)用；專利號(hào)：ZL 2022 1 0296353.5；2023. 11. 24

(7)劉新華，劉明明，石靜波，陳星，閆堯瑤，肖云，張照燕；一種漢黃芩素衍生物及其制備方法與應(yīng)用；專利號(hào)：ZL 2022 1 0379930.7；2023. 11. 24

(8)劉新華，陳星，石靜波，劉明明，閆堯瑤，張照燕，張發(fā)敏，一種嘧啶-2,4-二胺類化合物及其制備方法與應(yīng)用；專利號(hào)：ZL 2021 1 0129457.2；2024. 3. 1

(9)劉新華，石靜波，劉明明，張興星，閆堯瑤，王宇蒙，肖云，江瀚，佘梓濠，吳磊，一種3-芳雜環(huán)取代苯基衍生物及其制備方法與用途，專利號(hào)：ZL2022 1 0891482.9；2024. 3. 26